pmKaxxte
(Plasmid
#113630)
-
Purposeto test Cas9 gRNA efficiency or HR-capacity
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 113630 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backboneunknown
-
Vector typeMammalian Expression
Growth in Bacteria
-
Bacterial Resistance(s)Kanamycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert namemKaxxte2.5
-
Alt namemKate2.5
- Promoter CMV
Cloning Information
- Cloning method Unknown
- 5′ sequencing primer unknown (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
-
A portion of this plasmid was derived from a plasmid made bymKate2.5 from Michael Davidson (Addgene plasmid # 54828)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
One clones a fragment of DNA sequence at the MCS, then uses a targeted nuclease, such as Cas9 to trigger a double-strand break. This is then repaired by homologous recombination resulting in restoration of an intact mKate2.5 fluorescent protein (cloned from Addgene #54828). It can be used to test Cas9 gRNA efficiency, as it was in the paper, or HR-capacity in different cells.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pmKaxxte was a gift from Ken Mills (Addgene plasmid # 113630 ; http://n2t.net/addgene:113630 ; RRID:Addgene_113630) -
For your References section:
Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability. Liberante FG, Lappin K, Barros EM, Vohhodina J, Grebien F, Savage KI, Mills KI. Sci Rep. 2019 Feb 25;9(1):2678. doi: 10.1038/s41598-019-39591-7. 10.1038/s41598-019-39591-7 PubMed 30804405